Get the Stockscreener App
0.00
100.00%
-9.02
Range Cancer Therapeutics Etf stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$9.02
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$15.94
Range Cancer Therapeutics Etf Stock (CNCR) Company Profile
Name
Range Cancer Therapeutics Etf
Sector
Industry
Phone
-
Address
-
Compare CNCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNCR
Range Cancer Therapeutics Etf
|
0.00 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
328.90 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
667.80 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
671.16 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
254.09 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
605.49 | 124.43B | 0 | 0 | 0 | 0.00 |
Range Cancer Therapeutics Etf Stock (CNCR) Latest News
5 Small-cap Biotech ETFs to Watch in 2025 - Investing News Network
Best Biotech Stocks to Buy in 2025 - The Motley Fool
Unlocking Cures: How AI is Reshaping Cancer Research & Healthcare ETFs? - TradingView
N2OFF Stockholders Approve Merger With Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer - 富途牛牛
Investing in the DNA of Tomorrow: Explore Gene Stocks and Genomics ETFs - Investing News Network
Exploring the SPDR S&P Biotech ETF (XBI) for Biotech Industry Exposure - AInvest
4 Cancer Stocks to Consider in 2025 - The Motley Fool
Range Cancer Therapeutics ETF (NASDAQ: CNCR)Share Price - intelligentinvestor.com.au
When the Price of (CNCR) Talks, People Listen - news.stocktradersdaily.com
ICE to Expand NYSE Index Family With Launch of U.S. Tech Index and Broader Range of NYSE-Listed Indices - The Globe and Mail
The Best Biotech Stocks to Buy - Morningstar
When (CNCR) Moves Investors should Listen - news.stocktradersdaily.com
Percheron Acquires Cancer Therapy Licence - Sharecafe
Where are the Opportunities in (CNCR) - news.stocktradersdaily.com
Caris Life Sciences IPO Prices Above Range to Raise $494 Million - Bloomberg
Guardian Capital Announces June 2025 Cash Distributions for Guardian Capital ETFs - The Globe and Mail
(CNCR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor - Yahoo Finance
This ETF Could Turn $500 Per Month Into a $851,000 Portfolio Paying $30,000 in Annual Dividend Income - The Globe and Mail
Summit stock down after cancer trial data (update) (NASDAQ:SMMT) - Seeking Alpha
Friday's big stock stories: What’s likely to move the market in the next trading session - CNBC
ETF Channel: Range Cancer Therapeutics ETF Implied Analyst Target Price $20.61, Upside 132.35% - AInvest
Trend Tracker for (CNCR) - news.stocktradersdaily.com
Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA - Yahoo Finance
CIBC Asset Management launches three new actively managed CIBC ETFs, expanding its cash management and fixed income ETF suite - The Globe and Mail
Avacta Group Announces Investor Webinar on Latest Cancer Therapy Developments - TipRanks
Weekly ETF Industry Recap: U.S., Europe, and Canada HighlightsMay 5-10, 2025 - Trackinsight
Exchange Traded Concepts to Close and Liquidate the Range Cancer Therapeutics ETF - The Joplin Globe
Learn to Evaluate (CNCR) using the Charts - news.stocktradersdaily.com
Cold Spring Harbor Laboratory’s Ludmila Pollock lauded as fellow of AAAS - TBR News Media
Mythic Therapeutics Presents Preclinical Data Demonstrating Potent Efficacy of MYTX-011 Across a Broad Range of Tumor Xenograft Models Harboring Clinically Relevant Mutations at the American Association for Cancer Research (AACR) Annual Meeting - Yahoo Finance
Long Term Trading Analysis for (CNCR) - news.stocktradersdaily.com
7 Best Pharmaceutical Stocks to Buy for Income | Investing - US News Money
From Panic to Positioning: Top ETFs to Watch After Asia’s Tariff Shock - The Globe and Mail
10 Best Health Care Stocks to Buy for 2025 - US News Money
7 Top Gene-Editing Stocks to Buy | Investing - US News Money
Sellas Life Sciences Advances in Cancer Treatment Development - TipRanks
Buffer ETFs to Consider for Protecting Gains and Limiting Losses - The Globe and Mail
S&P 500 Index Funds Yield Just 1.3%. Consider Buying These 2 Low-Cost Vanguard ETFs to Generate More Passive Income. - The Globe and Mail
Bull or Bear, These 2 ETFs Don’t Care - The Globe and Mail
1 No-Brainer Artificial Intelligence (AI) ETF to Buy With $40 During the Nasdaq Sell-Off - The Globe and Mail
7 Best-Performing Biotech ETFs for March 2025 - NerdWallet
Top ETFs to Invest in Japan - The Globe and Mail
Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025 - Investing News Network
The Unstoppable Momentum in Oncology M&A - Nasdaq
2025 Outlook: Healthcare Technology & Innovation - ETF Trends
The Best Way to Invest in Gold Is... - The Globe and Mail
SELLAS Life Sciences Group, Inc. Secures $25 Million in Registered Direct Offering for Cancer Therapeutics Development - Nasdaq
5 US Longevity and Anti-aging Stocks to Watch in 2025 - Investing News Network
NEW: The Most Popular Sponsored Content of 2024 - Visual Capitalist
Investors Eye Biotech Stocks as Cancer Therapies Take Center Stage in 2025 - baystreet.ca
Range Cancer Therapeutics Etf Stock (CNCR) Financials Data
There is no financial data for Range Cancer Therapeutics Etf (CNCR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):